Credit Suisse AG boosted its stake in shares of AveXis, Inc. (NASDAQ:AVXS) by 36.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 63,228 shares of the company’s stock after buying an additional 16,876 shares during the period. Credit Suisse AG owned approximately 0.23% of AveXis worth $4,807,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in AVXS. Quantitative Systematic Strategies LLC purchased a new position in shares of AveXis during the first quarter valued at $201,000. Candriam Luxembourg S.C.A. purchased a new position in shares of AveXis during the first quarter valued at $1,901,000. Opus Point Partners Management LLC purchased a new position in shares of AveXis during the fourth quarter valued at $239,000. Swiss National Bank raised its position in shares of AveXis by 3.0% in the first quarter. Swiss National Bank now owns 27,400 shares of the company’s stock valued at $2,083,000 after buying an additional 800 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of AveXis by 11.7% in the first quarter. Vanguard Group Inc. now owns 1,194,809 shares of the company’s stock valued at $90,841,000 after buying an additional 124,750 shares during the period. 91.85% of the stock is owned by institutional investors and hedge funds.

AveXis, Inc. (NASDAQ AVXS) traded up 1.10% during trading on Friday, hitting $92.58. The stock had a trading volume of 167,607 shares. The company’s market cap is $2.96 billion. The company has a 50-day moving average price of $87.50 and a 200-day moving average price of $75.29. AveXis, Inc. has a 52-week low of $32.31 and a 52-week high of $97.77.

AveXis (NASDAQ:AVXS) last released its quarterly earnings data on Thursday, August 10th. The company reported ($2.07) EPS for the quarter, missing the consensus estimate of ($0.97) by $1.10. During the same quarter last year, the company earned ($0.68) EPS. Equities research analysts forecast that AveXis, Inc. will post ($6.00) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This report was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/19/avexis-inc-nasdaqavxs-shares-bought-by-credit-suisse-ag-updated-updated-updated.html.

Several equities analysts have weighed in on AVXS shares. Jefferies Group LLC reissued a “buy” rating and set a $108.00 price objective (up from $92.00) on shares of AveXis in a report on Friday, August 11th. BMO Capital Markets reissued an “outperform” rating and set a $95.00 price objective on shares of AveXis in a report on Friday, June 16th. Morgan Stanley reaffirmed an “overweight” rating and issued a $118.00 price target on shares of AveXis in a report on Wednesday, August 9th. Citigroup Inc. set a $100.00 price target on AveXis and gave the stock a “buy” rating in a report on Thursday, June 15th. Finally, Zacks Investment Research raised AveXis from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. AveXis currently has a consensus rating of “Buy” and a consensus price target of $102.45.

In other AveXis news, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $81.88, for a total transaction of $145,746.40. Following the completion of the transaction, the vice president now owns 1,780 shares of the company’s stock, valued at approximately $145,746.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 5,340 shares of company stock valued at $434,872 in the last three months. Insiders own 18.60% of the company’s stock.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Institutional Ownership by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Stock Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related stocks with our FREE daily email newsletter.